Raglan Pharmaceutical & Life Science Projects

Raglan Capital is involved as Founder or Co-Founder in a number of pharmaceutical and life science ventures including Poolbeg Pharma, Open Orphan plc and Amryt Pharma plc.

Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop shop” for Big Pharma seeking mid-stage products to license or acquire.

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.

With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001); a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) drug discovery programmes to accelerate the power of its human challenge model data and biobank.

Open Orphan plc

Open Orphan is a rapidly growing niche CRO pharmaceutical services group which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe’s only 24-bedroom quarantine clinic, with on-site virology facilities, it provides individually isolated rooms. To support its clients pre-clinical and clinical development of vaccines, antiviral and respiratory drugs, hVIVO offers a unique combination of virology and immunology laboratory services that position it as the world leader in this space. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission-ready data.

Open Orphan is comprised of two commercial specialist CRO services businesses, hVIVO and Venn Life Sciences, and is leveraging proprietary ‘-omic’ assets to unlock value for its clients. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and, in January 2020, it completed a merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls), pre-clinical, Phase I & II clinical trials design and execution. The acquisition of hVIVO created a European full pharma services group which broadened the Group’s customer base and, with its complementary specialist CRO services, widened the range of the Group’s service offerings.

Open Orphan Plc is a publicly traded company on the London AIM and Euronext Growth stock exchanges under the symbol ORPH. The company was created in-house by Raglan, following the success and lessons learned from our first life science project, Amryt Pharma plc.

For more information visit www.openorphan.com

Amryt Pharma plc

Amryt Pharma is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients diagnosed with rare or orphan diseases.

Amryt comprises a growing commercial business and a significant development pipeline. Their aim is to forge partnerships and collaborations that work for all. By interacting with stakeholders, they create a clear path for transformative medicines to reach those that need them.

In 2016, Raglan established Amryt Pharma Plc which is listed on both the London and Euronext exchanges. In 2020 Amryt, listed on the NASDAQ following the acquisition of Aegerion Pharmaceuticals in September 2019. Amryt is now an established European and North America orphan drug company and, in June 2020, it had a market capitalisation in excess of £281m.

Amryt’s lead drug candidate, FILSUVEZ® (formerly named AP101), is a potential treatment for Epidermolysis Bullosa (“EB”), a rare and distressing genetic skin disorder for which there is currently no treatment. The European and US market opportunity for EB is estimated to be in excess of €1.3 billion.

Amryt’s earlier stage product AP102 is focused on developing novel, next-generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing’s disease.

In addition, Amryt holds an exclusive licence to sell Lojuxta (lomitapide) across Europe, the Middle East, Northern Africa, Turkey, Israel and the Commonwealth of Independent States. Lojuxta is an approved treatment for adult patients with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia (“HoFH”). This disorder impairs the body’s ability to remove low-density lipoprotein cholesterol from the blood.

In March 2018, Amryt in-licensed a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders.

For more information on Amryt, please visit amrytpharma.com